세계의 인공 췌장 기기 시스템 시장 보고서 : 기기 유형별, 치료 유형별, 최종 사용자별, 지역별(2025-2033년)

The global artificial pancreas device systems (APDS) market size reached USD 2,579.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 6,027.2 Million by 2033, exhibiting a growth rate (CAGR) of 9.9% during 2025-2033.

APDS refers to a closed-loop or automated insulin delivery system that manages blood glucose levels by regulating the production of insulin. It consists of a continuous glucose monitor (CGM), a subcutaneous insulin infusion pump and a controller that links the monitor with the pump. It runs a complex algorithm that determines the adequate levels of insulin and time of delivery based on the evaluation of real-time glucose readings. It is primarily used to minimize the risks of extreme fluctuations of glucose levels in the body.

The increasing prevalence of pancreatic cancer, pancreatitis and other chronic ailments is one of the key factors driving the growth of the market. Furthermore, the growing occurrence of diabetes and obesity, due to age-related factors, physical inactivity and unhealthy dietary patterns, is also contributing to the widespread adoption of APDS across the globe. The rising demand for efficient diabetes monitoring and minimally invasive (MI) drug delivery systems is also providing a boost to the market growth. APDS automatically monitors the glucose levels and administers doses of insulin throughout the day in controlled amounts. Various technological innovations, including the development of software-based wireless systems that are integrated with automated controls, are further contributing to the market growth. Moreover, regulatory bodies and governments of various nations are significantly investing in research and development (R&D) for the improvement of healthcare infrastructure across the globe. For instance, the Food and Drug Association (US FDA) in the United States is approving an increasing number of new and innovative products, which is creating a positive outlook for the market in the country.

Key Market Segmentation:

Breakup by Device Type:

• Threshold Suspend Device Systems
• Control-to-Range Systems
• Control-to-Target Systems

Breakup by Treatment Type:

• Bi-hormonal
• Insulin Only
• Hybrid

Breakup by End-User:

• Hospitals
• Medical Centres
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Beta Bionics Inc., Bigfoot Biomedical Inc., Dexcom Inc., Inreda Diabetic B.V., Insulet Corporation, Johnson & Johnson, Medtronic Inc., F. Hoffmann-La Roche Ltd, Tandem Diabetes Care Inc., etc.

Key Questions Answered in This Report:

• How has the global artificial pancreas device systems market performed so far and how will it perform in the coming years?
• What are the key regional markets?
• What has been the impact of COVID-19 on the global artificial pancreas device systems market?
• What is the breakup of the market based on the device type?
• What is the breakup of the market based on the treatment type?
• What is the breakup of the market based on the end-user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global artificial pancreas device systems market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Artificial Pancreas Device Systems Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Device Type

• 6.1 Threshold Suspend Device Systems
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Control-to-Range Systems
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Control-to-Target Systems
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Treatment Type

• 7.1 Bi-hormonal
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Insulin Only
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Hybrid
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End-User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Medical Centres
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Beta Bionics Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Bigfoot Biomedical Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Dexcom Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Inreda Diabetic B.V.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Insulet Corporation
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Johnson & Johnson
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Medtronic Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 F. Hoffmann-La Roche Ltd
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Tandem Diabetes Care Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials